Andromeda Phase III Trial Costs Weigh on Andromeda Results

Published: Aug 20, 2007

IDB Holding Corp. Ltd. (TASE:IDBH) subsidiary Clal Biotechnology Industries Ltd. (TASE: CBI) today published its financial report for the second quarter of 2007. The company posted a net loss of NIS 10.3 million on NIS 8.1 million revenue. The second quarter loss was almost double the NIS 5.7 million loss for the corresponding quarter.

Back to news